ClinicalTrials.gg
RecruitingNCT06634069MJIP1_0Updated Apr 14, 2026

Study SOLACE SEPSIS

A Phase 2 interventional study of Sodium Lactate and 3% NaCl in Septic Shock and Intracranial Hypertension, sponsored by University Hospital Pilsen. Recruiting at 1 site in Czechia. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by University Hospital Pilsen · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Shock, Septic with a site in Czechia — 2 open to participants now, 2 under way, none of them phase 3. Shock, Septic · Czechia.

Planned enrollment
10th of 11
40 · median 277
Started
2024
the only one that year
Phase 2
3 of 19
1 open now
Registered
19th of 19
by date

Among the 19 studies in Shock, Septic with a site in Czechia, this one is the 10th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2024, is one of 3 in phase 2, and was the 19th registered.

Shock, Septic

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

Browse Shock, Septic studies →

Open to participants now

2 of the 19 studies in Shock, Septic with a site in Czechia are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Shock, Septic with a site in Czechia, or all of them as a file.
02

Study summary

A Pilot, Randomized, Double-Blinded, Controlled Study of Hemodynamic and Acid Base Effects of 0.5M Sodium Lactate and 3% Saline Solutions in Septic Shock Patients

Read the detailed description

This study investigates two resuscitation fluids that are being used off label for the treatment of patients suffering from septic shock and also in patients with intracranial hypertension in intensive care.

03

Conditions studied

  • Septic Shock
  • Intracranial Hypertension

Keywords

  • intracranial hypertension
  • septic shock
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects will be eligible for the trial if they meet all of the following criteria:

    1. Age criteria: 18 - 90 years
    2. Septic shock - Sepsis 3 criteria :

      1. acute change in total SOFA score ≥ 2 due to infection
      2. use of vasopressor drug to maintain target mean arterial pressure ≥ 65 mmHg
      3. blood lactate level ≥ 2 mmol/L within last 24 hours
    3. Likely need for fluid resuscitation

      1. poor peripheral perfusion as evidenced by 2 out of 4: i. peripheral cyanosis with delayed capillary refill ≥ 3 seconds ii. low urinary output (\< 0.5 ml/kg/hour for at least 6 hours) iii. central venous O2 saturation \< 70% iv. clouded sensorium/poor mentation
      2. dynamic assessment of preload responsiveness as evidenced by 1 out of 3: i. positive passive leg raising test ii. pulse pressure variation and / or stroke volume variation2, both > 12% iii. distensibility index of inferior vena caval diameter > 12%
    4. Signed the relevant form

Exclusion criteria

Exclusion Criteria:

  • Subjects will not be eligible for the trial if they meet any of the following criteria:

    1. Poor transthoracic echo windows
    2. Actual body weight > 160 kg
    3. Hypernatremia: [Na] > 150 mEq/L
    4. Cardiac tamponade
    5. Uncorrected severe valvular heart disease or life-threatening arrhythmia
    6. Moribund patients likely to die before the study protocol is completed
    7. Patients with absolute indication for immediate acute hemodialysis/hemofiltration (within 2 hrs) based on pH \< 7.0, K > 7.0mmol/L
    8. Severe liver dysfunction defined by total serum > 120 umol/l
    9. Pregnancy and lactation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Group 1

    Patients suffering from septic shock who require fluid resuscitation get 0.5M HSL (containing 504mM of sodium and lactate)

    Drug: Sodium Lactate

  • Active comparator
    Group 2

    Patients suffering from septic shock who require fluid resuscitation get 3% NaCl (containing 513mM of sodium and chloride)

    Drug: 3% NaCl

Interventions

06

What researchers measure

Primary outcomes

  1. haemodynamic effects

    SV is the amount of blood that leaves the left ventricle with every beat cycle and is calculated by measuring the Doppler flow in the aortic valve. Unit: ml

    Time frame: at time of start of infusion, at 30 minutes and at 60 minutes from the start of the respective fluid bolus

Secondary outcomes

  1. acid-base effect

    Diagnostic approach to acid-base changes is based on the assessment of bicarbonate buffer system, in which pH is determined by the ratio of \[HCO3-\] to pCO2 meassured by a POC whole-blood analyzer system Unit: \[HCO3-\] - mmol/l, pCO2 - kPa

    Time frame: at time of start of infusion, at 30 minutes and at 60 minutes from the start of the respective fluid bolus

  2. anti-inflammatory effect

    Inflammatory markers as CRP, procalcitonin, interleukin-6 and feritin are sepcific indicators linked to degree of inflammation and determined by regular biochemical analysis. The dynamics of parameters after the study fluid administration will be evaluated. Unit: CRP - mg/l, procalcitonin - ug/l, interleukin-6 - ng/l, ferritin - ug/l

    Time frame: parameters measured within the last 24 hours prior to start of infusion and within 24 hours after the study fluid infusion.

  3. Safety - Incidence of adverse events and reactions

    Incidence of adverse events and reactions according to following Adverse Events of Special Interest (AESI) and descriptive analysis of the incidence of any adverse events and reactions during participation in the study in both study arms. AEs are defined according to the valid definitions for clinical trials as imposed by legislation (Directive 2001/20/EG).

    Time frame: 30 days after intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Not yet decided to sharing IPD.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Oct 2027, 35 months after the start.

Of 36 non-industry phase 2 interventional studies under Shock, Septic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 42. This study's planned 35 months is above that.

Counting every sponsor, half of 41 studies reached it within 29 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2024
First posted
Oct 9, 2024
StartActual
Nov 24, 2024
Primary completionEst.
Oct 31, 2027
CompletionEst.
Oct 31, 2027
Last update
Apr 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06634069
Lead sponsor
University Hospital Pilsen
Responsible party
Sponsor
First posted
Oct 9, 2024
Start date
Nov 24, 2024
Primary completion
Oct 31, 2027 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Apr 14, 2026

Study contacts

Miroslav Kříž, MD
Contact
krizm@fnplzen.cz
+420732850912
Marek Nalos, MD
Contact
marek.nalos@gmail.com

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium Lactate

Start the discussion